



# MAYFLOWERS-0B-20: A Prospective Study Evaluating Maternal and FetaL Outcomes in the ERa of ModulatorS (MAYFLOWERS)

Status: Recruiting

## **Eligibility Criteria**

Sex: Female Age Group: 16 years and over This study is NOT accepting healthy volunteers

#### Inclusion Criteria:

- at least 16 years old - pregnant, intending to continue pregnancy - enrolled in the Cystic Fibrosis Foundation Patient Registry (CFFPR)

#### **Exclusion Criteria:**

- none

## Conditions & Interventions

Conditions: Rare Diseases, Respiratory System Keywords: Clinics and Surgery Center (CSC), Cystic Fibrosis, Pregnancy

### More Information

**Description:** This study is being done to look at how pregnancy affects the health of women with cystic fibrosis (CF) and to look at the health of babies born to women with CF. It is expected that most but not all women will be taking the newest CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) modulator medication called TRIKAFTA®. It is not known how this medication will affect the health of mother and infant.

Study Contact: Mary Bailey - mpbailey@umn.edu

Principal Investigator: Joanne Billings IRB

Number: SITE00001209

Thank you for choosing StudyFinder. Please visit http://studyfinder.umn.edu to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.